Effects of treatment interruption due to patient convenience on treatment of once a week teriparatide

다국어 초록 (Multilingual Abstract)

Objectives: Once-weekly teriparatide (W-TPTD) is an effective drug for patients with osteoporosis; however, some patients discontinue W-TPTD owing to its adverse drug reactions (ADRs). Sequential treatment with W-TPTD and antiresorptive therapy may be effective in treating such patients. In this study, we evaluate the efficacy of this sequential treatment regimen. Methods: This retrospective study was conducted at a single institution in Japan. The target subjects were patients with osteoporosis who started W-TPTD treatment. The subjects who received W-TPTD for 6 months or morewere divided into3 groups: TTT (W-TPTD for 18 months); TBT (sequentialtreatmentof W-TPTD/bisphosphonates/W-TPTD; each for 6 months); and TET (sequential treatment of W-TPTD/ elcatonin/W-TPTD,each for 6months) groups. The efficacyendpoints were bonemineral densities (BMD) in the lumbar spine and femur. Results: Lumbar spine BMD in groupTBT increased significantlyby1.6% (P¼0.023), 2.9% (P¼0.001), and 4.4% (P < 0.001) after 6,12, and 18 months, respectively, compared with baseline values. In group TET, it increased by 2.1%, (P ¼ 0.001), 1.3% (P ¼ 0.066), and 3.0% (P ¼ 0.015) after 6, 12, and 18 months, respectively. A significant increase was observed only after 6 and 18 months. In group TTT, it increased significantly by 3.3% (P ¼ 0.023), 5.1% (P ¼ 0.019), and 7.1% (P ¼ 0.010) after 6, 12, and 18 months, respectively. However, no significant difference in total hip BMD was observed among all three groups. No serious ADRs were reported. Conclusion: Inpatients who discontinue treatment with W-TPTD due to ADRs, sequential treatment with W-TPTD and antiresorptive therapy would be beneficial.

참고문헌 (Reference)

1 Lindsay R, "Teriparatide for osteoporosis : importance of the full course" 27 : 2395-2410, 2016

2 Eastell R, "Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)" 24 : 726-736, 2009

3 Nakamura T, "Randomized Teriparatide [human parathyroid hormone(PTH)1-34] Once-Weekly Efficacy Research(TOWER)trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk" 97 : 3097-3106, 2012

4 Black DM, "One year of alendronate after one year of parathyroid hormone(1-84)for osteoporosis" 353 : 555-565, 2005

5 Fujita T, "Once-weekly injection of low-dose teriparatide (28.2 mg) reduced the risk of vertebral fracture in patients with primary osteoporosis" 94 : 170-175, 2014

6 Takao KR, "Latest research progress on parathyroid hormone therapy : effects of administration frequency on bone metabolism and histomorphometry" 43 : 467-471, 2017

7 Zebaze R, "Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide" 99 : 80-84, 2017

8 Khoo BC, "In vivo shortterm precision of hip structure analysis variables in comparison with bone mineral density using paired dual-energy X-ray absorptiometry scans from multi-center clinical trials" 37 : 112-121, 2005

9 Beck TJ, "Hip structural analysis (HSA) program (BMD and structural geometry methodology)" Johns Hopkins University 2003

10 Broy SB, "Fracture risk prediction by non-BMD DXA measures : the 2015 ISCD official positions Part 1 : hip geometry" 18 : 287-308, 2015

11 Obermayer-Pietsch BM, "Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment" 23 : 1591-1600, 2008

12 Boonen S, "Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis" 93 : 852-860, 2008

13 Di Gregorio S, "Comparison between different bone treatments on areal bone mineral density(aBMD)and bone microarchitectural texture as assessed by the trabecular bone score(TBS)" 75 : 138-143, 2015

14 Senn C, "Comparative effects of teriparatide and ibandronate on spine bone mineral density(BMD)and microarchitecture(TBS)in postmenopausal women with osteoporosis : a 2-year open-label study" 25 : 1945e51-, 2014

15 Inoue J, "Bone changes with long term administration of low dose 1-34 human PTH on adult beagles" 59 : 409-427, 1985

16 Reeve J, "Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis : a multicentre trial" 280 : 1340-1344, 1980

17 Yamane H, "Acute development of cortical porosity and endosteal naïve bone formation from the daily but not weekly short-term administration of PTH in rabbit" 12 : e0175329-, 2017